Evidence map›Paper›PMID 27822286›Full record

ArticleIranian journal of psychiatry and behavioral sciences2016

Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study.

Mercede Samiei, Mohammad Vahidi, Omid Rezaee, Azadeh Yaraghchi, Reza Daneshmand

Open access · hybridAbstract read
In one paragraph

Article in Iranian journal of psychiatry and behavioral sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019
    Pooled it
  2. Pooled it
  3. Article
  4. Pharmacotherapy treatment of stimulant use disorder.The mental health clinician · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mercede SamieiDepartment of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran.
Mohammad VahidiDepartment of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran.
Omid RezaeeDepartment of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran.
Azadeh YaraghchiFaculty of Psychology, Science and Research Branch, Islamic Azad University, Tehran, IR Iran.
Reza DaneshmandSubstance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, IR Iran.
University of Social Welfare and Rehabilitation Sciences · IRIslamic Azad University, Science and Research Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferent studies have suggested that antipsychotic medications of the first generation have better effectiveness for the treatment of psychotic symptoms compared with antipsychotic medications of the second generation.

objectivesThe current study was the first pilot study in Iran that compared Haloperidol with Risperidone in the treatment of positive symptoms of psychosis among a group of methamphetamine-dependent patients. MATERIALS AND

methodsThis randomized clinical trial was designed and conducted in 2012. Overall, 44 patients who met the diagnostic and statistical manual of mental disorders, fourth edition-text revised (DSM.IV-TR) criteria for methamphetamine-associated psychosis (MAP) and were hospitalized at Razi psychiatric hospital in Tehran were selected. Patients (1: 1) were randomly divided to two groups. Overall, 22 subjects received Haloperidol (5 - 20 mg) and 22 subjects received Risperidone (2 - 8 mg). All subjects were assessed at baseline, during three consecutive weeks of treatment and one week after treatment (i.e., follow-up). Scale of assessment of positive symptoms (SAPS) was completed for each subject.

resultsThe study findings indicated that both Haloperidol (< 0.05) and Risperidone (< 0.05) were similarly applicable in the treatment of MAP but no differential effectiveness was found between the two medications. The treatment effects of both medications increased in the first two weeks of treatment and remained stable in the second two weeks.

conclusionsRisperidone and Haloperidol are two effective antipsychotic medications for the treatment of positive symptoms of MAP but other aspects of these two neuroleptic medications such as the long-term treatment effects should be studied. Further studies with more samples and longer follow-ups are suggested.

Indexed as

HaloperidolMethamphetaminePsychosisRisperidoneTreatment

Identifiers

PMID27822286
PMCPMC5097836
OpenAlexW2510195332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.